MCID: CHL014
MIFTS: 60

Cholera

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Cholera

MalaCards integrated aliases for Cholera:

Name: Cholera 12 77 54 60 56 44 3 45 15 74
Vibrio Cholerae 12 15
Cholera Due to Vibrio Cholerae 12
Cholera - Vibrio Cholerae 12
Vibrio Cholerae Infection 54

Characteristics:

Orphanet epidemiological data:

60
cholera
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),<1/1000000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1498
ICD9CM 36 001 001.0 001.9
MeSH 45 D002771
SNOMED-CT 69 61972007 63650001
MESH via Orphanet 46 D002771
ICD10 via Orphanet 35 A00.0 A00.1 A00.9
UMLS via Orphanet 75 C0008354
Orphanet 60 ORPHA173
UMLS 74 C0008354

Summaries for Cholera

MedlinePlus : 44 Cholera is a bacterial infection that causes diarrhea. The cholera bacterium is usually found in water or food that has been contaminated by feces (poop). Cholera is rare in the US. You may get it if you travel to parts of the world with poor water and sewage treatment. Outbreaks can also happen after disasters. The disease is not likely to spread directly from person to person. Cholera infections are often mild. Some people don't have any symptoms. If you do get symptoms, they usually start 2 to 3 days after infection. The most common symptom is watery diarrhea. In some cases, the infection can be severe, causing lots of watery diarrhea, vomiting, and leg cramps. Because you quickly lose body fluids, you are at risk for dehydration and shock. Without treatment, you could die within hours. If you think that you might have cholera, you should get medical care right away. Doctors diagnose cholera with a stool sample or rectal swab. Treatment is the replacement of the fluid and salts that you lost through the diarrhea. This is usually with a rehydration solution that you drink. People with severe cases may need an I.V. to replace the fluids. Some of them may also need antibiotics. Most people who get fluid replacement right away will recover. There are vaccines to prevent cholera. One of them is available for adults in the U.S. Very few Americans need it, because most people do not visit areas that have an active cholera outbreak. There are also simple steps you can take to help to prevent cholera infection: Use only bottled or purified water for drinking, washing dishes, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Wash your hands often with soap and clean water Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables Centers for Disease Control and Prevention

MalaCards based summary : Cholera, also known as vibrio cholerae, is related to pancreatic cholera and wdha syndrome, and has symptoms including fever and pruritus. An important gene associated with Cholera is ARF1 (ADP Ribosylation Factor 1), and among its related pathways/superpathways are Metabolism of proteins and GPCR Pathway. The drugs Formaldehyde and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include colon, skin and small intestine, and related phenotypes are no effect and immune system

Disease Ontology : 12 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.

NIH Rare Diseases : 54 Cholera is an infection of the small intestines that is caused by the bacterium Vibrio cholera. The condition can range from mild to severe and many affected people may have no obvious signs or symptoms. Approximately 5-10% of infected people will have severe disease with watery diarrhea and vomiting leading to rapid fluid loss, dehydration, and shock. If left untreated, this can cause acute renal failure, severe electrolyte imbalances, coma, or even death. People develop cholera when they eat food or drink water that is contaminated with Vibrio cholera. The condition occurs most often in places that lack water treatment and have poor sanitation and inadequate hygiene. Treatment aims to prevent dehydration and replace the fluids and salts that are lost through diarrhea.

Wikipedia : 77 Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae.... more...

Related Diseases for Cholera

Diseases related to Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 pancreatic cholera 12.5
2 wdha syndrome 12.0
3 vipoma 11.8
4 gastroenteritis 11.6
5 secretory diarrhea 11.4
6 diarrhea 10.7
7 plague 10.6
8 yellow fever 10.6
9 variola major 10.6
10 smallpox 10.6
11 epidemic typhus 10.6
12 cerebrotendinous xanthomatosis 10.6
13 pertussis 10.5
14 typhoid fever 10.5
15 dysentery 10.3
16 influenza 10.3
17 tropical calcific pancreatitis 10.2
18 tetanus 10.2
19 shigellosis 10.2
20 cellulitis 10.2
21 malaria 10.1
22 anthrax disease 10.1
23 spondyloocular syndrome 10.1
24 acute diarrhea 10.1
25 salmonellosis 10.1
26 diphtheria 10.1
27 glioma 10.1
28 cholecystitis 10.1
29 mouth disease 10.1
30 elastosis perforans serpiginosa 10.1
31 cystic fibrosis 10.1
32 hepatitis 10.1
33 colitis 10.1
34 chlamydia 10.1
35 fasciitis 10.1
36 necrotizing fasciitis 10.1
37 hepatitis b 10.0
38 liver cirrhosis 10.0
39 newcastle disease 10.0
40 pneumonia 10.0
41 haemophilus influenzae 10.0
42 helicobacter pylori infection 10.0
43 dengue virus 10.0
44 exanthem 10.0
45 bone resorption disease 10.0
46 meningoencephalitis 10.0
47 pasteurellosis 10.0
48 acalculous cholecystitis 10.0
49 meningitis 10.0
50 allergic encephalomyelitis 10.0

Graphical network of the top 20 diseases related to Cholera:



Diseases related to Cholera

Symptoms & Phenotypes for Cholera

UMLS symptoms related to Cholera:


fever, pruritus

GenomeRNAi Phenotypes related to Cholera according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADCY1 ADCY10 ADORA2B ARF1 ARF3 ARF4

MGI Mouse Phenotypes related to Cholera:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 ADORA2B CD79A CFTR EGF ERO1A GNAI1

Drugs & Therapeutics for Cholera

Drugs for Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-00-0 712
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
12 Prednisolone acetate Phase 4
13 Cholera Toxin Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 Methylprednisolone Acetate Phase 4
15 Calcineurin Inhibitors Phase 4
16 Cyclosporins Phase 4
17 Immunosuppressive Agents Phase 4
18
Azithromycin Approved Phase 3 83905-01-5 447043 55185
19
Ciprofloxacin Approved, Investigational Phase 3,Phase 1 85721-33-1 2764
20
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6 32051
21
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 441411 12560
22 Acidophilus Phase 3
23 Anti-Infective Agents Phase 3,Phase 1,Phase 2
24 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1
25 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 1
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Phase 1
28 Trace Elements Phase 3,Phase 1,Phase 2
29 Micronutrients Phase 3,Phase 1,Phase 2
30 Nutrients Phase 3,Phase 1,Phase 2
31 Erythromycin stearate Phase 3
32 Erythromycin Estolate Phase 3
33 Erythromycin Ethylsuccinate Phase 3
34 Immunoglobulins Phase 3,Phase 2,Not Applicable
35 Antibodies Phase 3,Phase 2,Not Applicable
36
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
37
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
38
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
39
Secnidazole Approved Phase 1, Phase 2 3366-95-8
40
Histamine Approved, Investigational Phase 2 51-45-6 774
41
Phenol Approved, Experimental Phase 1, Phase 2 108-95-2 996
42
Vitamin C Approved, Nutraceutical Phase 2,Phase 1 50-81-7 54670067 5785
43
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
44
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
45 Dermatologic Agents Phase 1, Phase 2
46 Anthelmintics Phase 1, Phase 2
47 Antiparasitic Agents Phase 1, Phase 2
48 Antimitotic Agents Phase 1, Phase 2
49 Antiprotozoal Agents Phase 1, Phase 2
50 Astringents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Completed NCT01949675 Phase 4
2 Evaluation of a Boosting Regimen With Oral Cholera Vaccine Completed NCT01579448 Phase 4
3 Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Completed NCT01524640 Phase 4
4 A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children Completed NCT00760825 Phase 4
5 Mucosal Response in Immunocompromised Host Completed NCT01109914 Phase 4
6 Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Completed NCT00125008 Phase 4
7 New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Recruiting NCT03373669 Phase 4
9 CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
10 Blood Donor CVD 9000 Recruiting NCT03724357 Phase 4 Vaxchora
11 VAXCHORA Pediatric Study Active, not recruiting NCT03220737 Phase 4
12 Safety and Immunogenicity of a New Formulation of Euvichol® Unknown status NCT02502331 Phase 3
13 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea Unknown status NCT00534170 Phase 3
14 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Completed NCT02434822 Phase 3
15 Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Completed NCT02027207 Phase 3
16 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed NCT01895855 Phase 3
17 Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata Completed NCT00289224 Phase 3
18 Ciprofloxacin Multiple Dose for Adult Cholera Completed NCT00741052 Phase 3 Ciprofloxacin;Azithromycin
19 Zinc Supplementation in Cholera Patients Completed NCT00226616 Phase 3 Zinc
20 Single Dose Azithromycin in the Treatment of Adult Cholera Completed NCT00229944 Phase 3 Azithromycin
21 Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Completed NCT00142272 Phase 3 Ciprofloxacin
22 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed NCT02100631 Phase 3
23 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Completed NCT02094586 Phase 3
24 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
25 To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Completed NCT02164110 Phase 3
26 Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children Completed NCT02556996 Phase 3
27 Improving Rotavirus Vaccine Immune Response Completed NCT01825109 Phase 3
28 A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Completed NCT02133690 Phase 3
29 Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine Recruiting NCT03581734 Phase 3
30 Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Unknown status NCT00548054 Phase 2
31 Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Completed NCT02742558 Phase 2
32 Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata Completed NCT00119197 Phase 2
33 Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Completed NCT01233362 Phase 2
34 To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh Completed NCT01042951 Phase 2
35 Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Completed NCT00419133 Phase 2
36 Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Completed NCT02823899 Phase 1, Phase 2
37 Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Completed NCT00128011 Phase 2
38 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
39 Studies of Immune Responses to Orally Administered Vaccines in Developing Country Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
40 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Completed NCT02145377 Phase 2
41 Field Application of Shanchol in Adults in Bangladesh Completed NCT01762930 Phase 2 Shanchol
42 Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults Completed NCT00741637 Phase 2
43 Slow Versus Rapid Rehydration of Severely Malnourished Children Completed NCT02216708 Phase 2
44 Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 Completed NCT03576183 Phase 2
45 Modified ORS Solution for Severely Malnourished Children Completed NCT01821586 Phase 2
46 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
47 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh Completed NCT02531802 Phase 1, Phase 2
48 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Recruiting NCT03251495 Phase 2 Vaxchora
49 Extended Dose Intervals With Oral Cholera Vaccine in Cameroon Active, not recruiting NCT03719066 Phase 2
50 Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis Terminated NCT00751933 Phase 2

Search NIH Clinical Center for Cholera

Cochrane evidence based reviews: cholera

Genetic Tests for Cholera

Anatomical Context for Cholera

MalaCards organs/tissues related to Cholera:

42
Colon, Skin, Small Intestine, T Cells, Testes, B Cells, Eye

Publications for Cholera

Articles related to Cholera:

(show top 50) (show all 6184)
# Title Authors Year
1
Efficient Cholera Toxin B Subunit-Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration. ( 30536989 )
2019
2
Increase in Reported Cholera Cases in Haiti Following Hurricane Matthew: An Interrupted Time Series Model. ( 30594260 )
2019
3
Genomic insights into the 2016-2017 cholera epidemic in Yemen. ( 30602788 )
2019
4
Epidemiological description of a protracted cholera outbreak in Tonj East and Tonj North counties, former Warrap State, South Sudan, May-Oct 2017. ( 30606126 )
2019
5
Adenylyl cyclase 6 expression is essential for cholera toxin-induced diarrhea. ( 30624615 )
2019
6
A new target to treat diarrhea in cholera? ( 30624702 )
2019
7
Strong inhibition of cholera toxin B subunit by affordable, polymer-based multivalent inhibitors. ( 30629410 )
2019
8
Repeated dose toxicity evaluation of a cold chain-free, live, attenuated oral cholera vaccine in Sprague Dawley rats. ( 30630696 )
2019
9
Fowl cholera and acute heart rupture in a backyard turkey. ( 30636539 )
2019
10
Oral cholera vaccination strategy: Self-administration of the second dose in urban Dhaka, Bangladesh. ( 30639459 )
2019
11
Protection of Chickens Against Fowl Cholera by Supernatant Proteins of Pasteurella Multocida Cultured in an Iron- Restricted Medium. ( 30640510 )
2019
12
Lessons Learned from Enhancing Sentinel Surveillance for Cholera in Post-Earthquake Nepal in 2016. ( 30652658 )
2019
13
Barbel cholera, a rare but still possible food-borne poisoning. Case report and narrative review. ( 30657109 )
2019
14
Cholera. ( 30663585 )
2019
15
Genomics can help to monitor cholera. ( 30670864 )
2019
16
Aptamer lateral flow assays for rapid and sensitive detection of cholera toxin. ( 30681077 )
2019
17
A cholera outbreak in a rural north central Nigerian community: an unmatched case-control study. ( 30683078 )
2019
18
Cholera toxin B induces interleukine-1β production from resident peritoneal macrophages through pyrin as well as NLRP3 inflammasome. ( 30689886 )
2019
19
The Cholera Phone: Diarrheal Disease Surveillance by Mobile Phone in Bangladesh. ( 30693862 )
2019
20
Global dynamics of an age-structured cholera model with multiple transmissions, saturation incidence and imperfect vaccination. ( 30696390 )
2019
21
Erratum for Withey et al., "Conjugated Linoleic Acid Reduces Cholera Toxin Production In Vitro and In Vivo by Inhibiting Vibrio cholerae ToxT Activity". ( 30696692 )
2019
22
Food insecurity and self-reported cholera in Haitian households: An analysis of the 2012 Demographic and Health Survey. ( 30699107 )
2019
23
Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults. ( 30703094 )
2019
24
Field evaluation of a locally produced rapid diagnostic test for early detection of cholera in Bangladesh. ( 30703097 )
2019
25
The global burden of cholera outbreaks in Niger: an analysis of the national surveillance data, 2003-2015. ( 30715523 )
2019
26
Epidemiological and molecular forensics of cholera recurrence in Haiti. ( 30718586 )
2019
27
Efficient Cholera Toxin B Subunit-Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration. ( 30724478 )
2019
28
Expression and active testing of VP7 from GCRV (Grass carp reovirus) fused with cholera toxin B subunit in rice calli. ( 30753891 )
2019
29
Publisher Correction: Genomic insights into the 2016-2017 cholera epidemic in Yemen. ( 30755740 )
2019
30
Examining health literacy on cholera in an endemic community in Accra, Ghana: a cross-sectional study. ( 31086499 )
2019
31
"It depends how one understands it:" a qualitative study on differential uptake of oral cholera vaccine in three compounds in Lusaka, Zambia. ( 31088376 )
2019
32
Frontier Warriors-Combating Cholera in Rural India. ( 31088605 )
2019
33
Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial. ( 31092224 )
2019
34
Cholera: an overview with reference to the Yemen epidemic. ( 29934743 )
2019
35
Exploring the development of a household cholera-focused health literacy scale in James Town, Accra. ( 30219358 )
2019
36
Reviving Phage Therapy for the Treatment of Cholera. ( 30395214 )
2019
37
Post-transcriptional regulation of cholera toxin production in Vibrio cholerae by the stringent response regulator DksA. ( 30444469 )
2019
38
Novel Cholera Toxin Variant and ToxT Regulon in Environmental Vibrio mimicus Isolates: Potential Resources for the Evolution of Vibrio cholerae Hybrid Strains. ( 30446560 )
2019
39
Microbiota Metabolite Short-Chain Fatty Acids Facilitate Mucosal Adjuvant Activity of Cholera Toxin through GPR43. ( 31076530 )
2019
40
Combating Cholera. ( 31069064 )
2019
41
Post-monsoon waterlogging-associated upsurge of cholera cases in and around Kolkata metropolis, 2015. ( 31063116 )
2019
42
A case of severe cholera imported from Bangladesh to Italy, 2017. ( 31055045 )
2019
43
Outbreak investigation of cholera outbreak in a slum area of urban Wardha, India: An interventional epidemiological study. ( 31041259 )
2019
44
Climate change, cyclones and cholera - Implications for travel medicine and infectious diseases. ( 31029753 )
2019
45
Comparison of the immunogenicity of Dukoral® oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial. ( 31029516 )
2019
46
Evaluation of an Emergency Bulk Chlorination Project Targeting Drinking Water Vendors in Cholera-Affected Wards of Dar es Salaam and Morogoro, Tanzania. ( 31017078 )
2019
47
Risk Factors Associated with the Recent Cholera Outbreak in Yemen: A Case-Control Study. ( 31010279 )
2019
48
Cholera in the time of Likes Inspirational Pathogens and an Important Pump. ( 31004789 )
2019
49
Recurrent Cholera Outbreaks, Democratic Republic of the Congo, 2008-2017. ( 31002075 )
2019
50
Vibriocidal Titer and Protection From Cholera in Children. ( 30997364 )
2019

Variations for Cholera

Expression for Cholera

Search GEO for disease gene expression data for Cholera.

Pathways for Cholera

Pathways related to Cholera according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 ADORA2B ARF1 ARF3 ARF4 ARF5 CFTR
2
Show member pathways
13.59 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
3
Show member pathways
13.26 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
4
Show member pathways
13.18 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
5
Show member pathways
13.06 ADCY1 CFTR EGF GNAI1 GNAS PLCB1
6
Show member pathways
13.04 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
7
Show member pathways
12.89 ADCY1 ADORA2B CD79A GNAI1 GNAS PLCB1
8 12.81 ADCY1 EGF GNAI1 GNAS PLCB1
9
Show member pathways
12.71 ADCY1 ADORA2B GNAI1 GNAS PLCB1
10
Show member pathways
12.66 ARF1 ARF3 ARF4 ARF5 ARL1
11
Show member pathways
12.61 ADCY1 EGF GNAI1 GNAS PLCB1
12
Show member pathways
12.55 ADCY1 ADORA2B ARF6 EGF GNAI1 GNAS
13
Show member pathways
12.54 ADCY1 EGF GNAI1 GNAS
14
Show member pathways
12.53 ADCY1 GNAI1 GNAS PLCB1
15
Show member pathways
12.51 ADCY1 GNAI1 GNAS PLCB1
16
Show member pathways
12.44 ARF1 CFTR ERO1A GNAS
17 12.37 ARF1 ARF3 ARF5 ARF6
18
Show member pathways
12.34 ADCY1 GNAI1 GNAS PLCB1
19 12.33 ADCY1 GNAI1 GNAS PLCB1
20
Show member pathways
12.22 ADCY1 ADORA2B GNAS PLCB1
21 12.22 ADCY1 ADCY10 CFTR GNAI1 GNAS
22
Show member pathways
12.19 ADCY1 ARF1 ARF6 EGF GNAS PLCB1
23
Show member pathways
12.13 ADCY1 GNAI1 GNAS PLCB1
24
Show member pathways
12.07 ADCY1 ADORA2B CFTR GNAI1 GNAS
25
Show member pathways
12.05 ADCY1 CFTR GNAI1 GNAS PLCB1
26 12 ADCY1 ADCY10 GNAI1 PLCB1
27 11.97 ADCY1 ADORA2B GNAI1 GNAS VIP
28 11.94 GNAI1 GNAS PLCB1
29
Show member pathways
11.94 ADCY1 ADORA2B GNAS PLCB1
30 11.93 ADCY1 GNAI1 GNAS PLCB1
31
Show member pathways
11.91 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
32
Show member pathways
11.89 ADCY1 EGF GNAI1 PLCB1
33 11.87 ADCY1 EGF GNAI1 PLCB1
34 11.86 GNAI1 GNAS PLCB1
35 11.85 ADCY1 GNAS PLCB1
36 11.85 ADCY1 GNAI1 GNAS PLCB1
37 11.81 ADCY1 GNAI1 GNAS
38 11.8 ADCY1 CFTR GNAS PLCB1
39 11.7 ADCY1 CFTR GNAS
40 11.67 GNAI1 GNAS PLCB1
41 11.67 GNAI1 GNAS PLCB1
42 11.6 GNAI1 GNAS PLCB1
43 11.54 ADCY1 GNAI1 GNAS
44 11.5 GNAI1 GNAS PLCB1
45 11.5 ADCY1 EGF GNAI1 GNAS PLCB1
46 11.49 ADCY1 GNAI1 GNAS
47 11.44 ADCY1 GNAS PLCB1
48 11.37 ADCY1 GNAI1 GNAS PLCB1
49 11.37 ARF1 ARF5 ARF6
50 11.34 ADCY1 GNAS PLCB1

GO Terms for Cholera

Cellular components related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.77 ADCY10 ARF1 ARF3 ARF5 GNAS
2 lysosomal membrane GO:0005765 9.62 CFTR EGF GNAI1 NEU1
3 glutamatergic synapse GO:0098978 9.43 ADCY1 ADORA2B ARF1 ARF4 ARF6 PLCB1
4 extracellular exosome GO:0070062 9.4 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
5 membrane GO:0016020 10.16 ADCY1 ADCY10 ADORA2B ARF1 ARF4 ARF5
6 plasma membrane GO:0005886 10 ADCY1 ADCY10 ADORA2B ARF1 ARF3 ARF4

Biological processes related to Cholera according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein transport GO:0015031 9.89 ARF1 ARF3 ARF4 ARF5 ARF6
2 intracellular protein transport GO:0006886 9.73 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
3 activation of MAPK activity GO:0000187 9.65 ADORA2B CXCL17 EGF
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.62 ADCY1 ADORA2B GNAS VIP
5 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 9.58 ARF3 ARF4 ARF5
6 cyclic nucleotide biosynthetic process GO:0009190 9.46 ADCY1 ADCY10
7 cAMP biosynthetic process GO:0006171 9.43 ADCY1 ADCY10
8 vesicle-mediated transport GO:0016192 9.43 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
9 activation of phospholipase D activity GO:0031584 9.37 ARF4 ARL1
10 cellular response to forskolin GO:1904322 9.33 ADCY1 CFTR GNAI1
11 Golgi to plasma membrane transport GO:0006893 8.92 ARF1 ARF3 ARF4 ARF5

Molecular functions related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.56 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.37 GNAI1 GNAS
3 phosphorus-oxygen lyase activity GO:0016849 9.32 ADCY1 ADCY10
4 guanyl nucleotide binding GO:0019001 9.26 GNAI1 GNAS
5 GTPase activity GO:0003924 9.23 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
6 adenylate cyclase activity GO:0004016 9.16 ADCY1 ADCY10

Sources for Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....